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ranscatheter Closure of Patent Foramen Ovale
ark Reisman, MD,* Ryan D. Christofferson, MD,* Jill Jesurum, PHD,* John V. Olsen, MD, FACC,*
errill P. Spencer, MD,† Kimberly A. Krabill, MD,* Lance Diehl, MD,* Sheena Aurora, MD,*
illiam A. Gray, MD*
eattle, Washington
OBJECTIVES The purpose of this study was to determine the effects of transcatheter patent foramen ovale
(PFO) closure on migraine frequency in patients with paradoxical cerebral embolism.
BACKGROUND The prevalence of migraine headache is higher in cryptogenic stroke patients with PFO than
in the general population. Previous studies have suggested that closure of the PFO may reduce
migrainous symptoms.
METHODS Between April 2001 and December 2003, 162 consecutive patients with paradoxical cerebral
embolism underwent transcatheter PFO closure for prevention of recurrent cryptogenic
stroke or transient ischemic attack. A one-year retrospective analysis of migraine symptoms
before and after PFO closure was performed.
RESULTS Active migraine was present in 35% (57 of 162) of patients, and 68% (39 of 57) experienced
migrainous aura; 50 patients were available for analysis at one year. Complete resolution of
migraine symptoms occurred in 56% (28 of 50) of patients, and 14% (7 of 50) of patients
reported a significant (50%) reduction in migraine frequency. Patients reported an 80%
reduction in the mean number of migraine episodes per month after PFO closure (6.8  9.6
before closure vs. 1.4  3.4 after closure, p  0.001). Results were independent of
completeness of PFO closure at one year.
CONCLUSIONS In patients with paradoxical cerebral embolism, migraine headaches are more frequent than
in the general population, and transcatheter closure of the PFO results in complete resolution
or marked reduction in frequency of migraine headache. (J Am Coll Cardiol 2005;45:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.055493–5) © 2005 by the American College of Cardiology Foundation
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sigraine headache is a common, often disabling, condition
nd represents a significant health care burden. Recent
vidence has shown that migraineurs who experience an
ura beforehand are twice as likely to have a patent foramen
vale (PFO) (41% to 48%) than the general population
16% to 20%) (1,2). Right-to-left cardiac shunt at rest
hrough a PFO also is more common in migraineurs with
ura (15%) than in control patients with PFO who do not
xperience migraines (0%) (1), suggesting that interatrial
ommunication may play a role in the pathogenesis of
igraines.
See page 496
Previous publications have demonstrated closure of the
FO in patients with cryptogenic stroke or decompression
llness may reduce migraine symptoms (3–6). The purpose
f this study is to report the effect of transcatheter PFO
losure on migraine frequency in patients with presumed
aradoxical cerebral embolism.
ETHODS
he study was descriptive, correlational, and retrospective.
he Western Institutional Review Board approved the
From the *Cardiovascular Research, Swedish Medical Center, and †Spencer
ascular Laboratories, Seattle, Washington.d
Manuscript received June 11, 2004; revised manuscript received October 14, 2004,
ccepted October 18, 2004.etrospective analysis. Between April 2001 and December
003, 162 consecutive patients with presumed paradoxical
mbolism underwent transcatheter PFO closure to prevent
ecurrent stroke or transient ischemic attack. Eligibility
riteria included a presumed paradoxical thromboembolic
vent evidenced by clinical and/or radiologic findings (com-
uted tomography, magnetic resonance imaging, or angio-
ram) and a provocable right-to-left shunt, confirmed by
ontrast, bilateral power m-mode transcranial Doppler (pm-
CD) and/or transesophageal echocardiography (7).
Using a percutaneous, transcatheter approach, a septal
ccluder device was implanted successfully in all patients.
hereafter, daily antiplatelet therapy consisted of 75 mg of
lopidogrel for three months and 325 mg of aspirin for six
onths. Symptom and standardized migraine question-
aires were administered at baseline and in follow-up to
ssess cardiac and neurologic status. Migraine events were
lassified according to International Headache Society cri-
eria (8). Migraine definitions of relief following closure
ere defined as: 1) complete absence of symptoms; 2)
ignificant, that is, 50% reduction in monthly frequency;
nd 3) minimal/none, that is, 50% reduction in monthly
igraine frequency.
Closure status and residual right-to-left shunt were eval-
ated serially using pm-TCD with measurements during
esting respiration and calibrated Valsalva. Final closure
tatus was based on the number of embolic tracks observed
uring calibrated Valsalva.
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Migraine Relief After PFO Closure February 15, 2005:493–5tatistical analysis. Data are reported as means standard
eviations. Pearson chi-square, and independent samples t
est and paired-samples t tests were used to compare
ategorical, nominal, and continuous variables, respectively.
arly and late follow-up of migraine frequency were com-
ared using a within-subjects repeated-measures analysis of
ariance. Assumptions of normality and homogeneity of
ariance were satisfied. The level of significance for all tests
as set at 0.05 (two-tailed). Data were analyzed using the
tatistical Package for the Social Sciences (version release
1.0.1, SPSS Inc., Chicago, Illinois).
ESULTS
hirty-five percent (57 of 162) of patients experienced
ctive migraine symptoms at the time of PFO closure and,
f these, 68% (39 of 57) had a history of migrainous aura.
able 1 shows that patients with migraine were younger,
ore likely to be female, and more likely to have a large
hunt (100 embolic tracks using pm-TCD) at rest (p 
.05) than patients without migraine. There were no sig-
ificant differences (p  NS) in the baseline characteristics
f migraineurs who experienced an aura beforehand (n 
9) and those who did not experience aura (n 18). Within
he migraine group, 7 patients had incomplete follow-up;
herefore, 50 migraineurs were included in the final analysis
n  50).
At a mean duration of follow-up of 37  23 weeks,
atients reported significantly fewer migraine episodes/
onth (6.8  9.6 before closure vs. 1.4  3.4 after closure,
 0.001). Migraine symptoms were completely relieved in
6% (28 of 50) and significantly (50%) reduced in 14% (7
f 50) of patients. Fifteen (30%) patients reported minimal
Abbreviations and Acronyms
PFO  patent foramen ovale
pm-TCD  power m-mode transcranial Doppler
able 1. Baseline Patient and Procedural Characteristics
Nonmigraineurs
(n  105)
Migraineurs
(n  57)
emographic data
Age (yrs)* 58  17 47  12
Female* 48 (46%) 38 (67%)
rocedural characteristics
Co-existing atrial septal aneurysm† 31 (30%) 14 (25%)
PFO balloon waist size, mm 13.2  3.8 12.9  2.9
Device size, mm 28.7  5.6 27.8  5.4
Closure device type
NMT CardioSEAL 99 (94%) 52 (91%)
AGA Amplatzer 6 (6%) 5 (9%)
ranscranial Doppler data (n  147)
Large shunt at rest*‡ 35/95 (37%) 28/52 (54%)
Large shunt at Valsalva*‡ 82/95 (86%) 50/52 (96%)
alues are n (%) or mean  SD. *Significance to p  0.05. †Protrusion of the
nteratrial septum with a base width 15 mm and mobile excursion 10 mm. ‡Morea
han 100 embolic tracks.
PFO  patent foramen ovale.50%) or no relief of migraine symptoms. In a subgroup of
1 patients who had serial assessment of migraine frequency
t early (18  17 weeks) and late follow-up (40  26
eeks), no significant differences in monthly migraine
requency were found between early (1.6  3.7) and late
1.1  2.6) follow-up (F  1.69, p  0.208), suggesting a
ersistent treatment effect. The degree of migraine relief did
ot vary according to migraine subtype (Fig. 1). In follow-
p, complete PFO closure (30 embolic tracks) was suc-
essfully achieved in 72% (36/50) of patients. Final closure
tatus did not influence the degree of migraine relief.
chi-square test  0.18, p  0.91).
ISCUSSION
his study supports published findings that migraine head-
che in cryptogenic stroke patients with PFO is more
revalent (35%) than the presence of migraine headache in
he general population (12%) (9). Similar to previously
ublished reports of migraine relief after PFO closure (3–5),
significant reduction in overall frequency of migraine
eadaches was observed, with patients reporting on average
n 80% reduction in monthly migraine events.
The significant treatment effect of transcatheter PFO
losure on migraine frequency suggests the possibility of a
ommon pathophysiologic substrate for selected patients
ith migraine and paradoxical embolism. This study is
imited, however, by its nonrandomized, uncontrolled de-
ign, small sample size, and possibility of recall bias and
lacebo effect. Although the reported placebo effect in large,
andomized trials of migraine prophylaxis (20% to 40%)
10) is significantly lower than the observed treatment effect
70%), it is possible the placement of an intracardiac device
ay have a more profound placebo effect than medical
herapies.
Migraine relief was independent of the completeness of
FO closure, suggesting either a type II error due to
nsufficient sample-size, an effect based on partial “filtration”
f microaggregates, or hypersensitivity of pm-TCD evalu-
igure 1. Migraine headache relief by migraine subtype according to
resence or absence of aura. Significant relief (Significant)  50%
eduction in monthly migraine frequency. No relief (None)  50%
eduction in monthly migraine frequency. Chi-square test 0.40, p 0.82
or the comparison between groups. Solid bars  migraine with aura (n 
8); ruled bars  migraine without aura (n  12).tion in quantifying residual shunt. It is possible that some
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February 15, 2005:493–5 Migraine Relief After PFO Closuref the treatment effect could be due to aspirin therapy rather
han PFO closure; however, this bias is debatable because
0% (25 of 50) of patients were taking aspirin before PFO
losure, and the known effect of aspirin on migraine relief is
odest (11). Although the effect of combination aspirin and
lopidogrel therapy on migraine frequency has not been
stablished, we observed sustained migraine relief after
ntiplatelet therapy was discontinued. The consistent ob-
ervations of this and other studies are provocative and
orthy of evaluation with a prospective, randomized trial
sing objective measures of migraine frequency and severity.
eprint requests and correspondence: Dr. Jill Jesurum, 801
roadway, Suite 927, Seattle, Washington 98104. E-mail:
ill.jesurum@swedish.org.
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